35 related articles for article (PubMed ID: 18842335)
1. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors.
Kusuma BR; Duerfeldt AS; Blagg BS
Bioorg Med Chem Lett; 2011 Dec; 21(23):7170-4. PubMed ID: 22014546
[TBL] [Abstract][Full Text] [Related]
3. Exploiting polarity and chirality to probe the Hsp90 C-terminus.
Forsberg LK; Davis RE; Wimalasena VK; Blagg BSJ
Bioorg Med Chem; 2018 Jul; 26(12):3096-3110. PubMed ID: 29720349
[TBL] [Abstract][Full Text] [Related]
4. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
5. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects.
Forsberg LK; Anyika M; You Z; Emery S; McMullen M; Dobrowsky RT; Blagg BSJ
Eur J Med Chem; 2018 Jan; 143():1428-1435. PubMed ID: 29137866
[TBL] [Abstract][Full Text] [Related]
6. Development of Noviomimetics as C-Terminal Hsp90 Inhibitors.
Anyika M; McMullen M; Forsberg LK; Dobrowsky RT; Blagg BS
ACS Med Chem Lett; 2016 Jan; 7(1):67-71. PubMed ID: 26819668
[TBL] [Abstract][Full Text] [Related]
7. Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of HSP90 family proteins.
Mathieu C; Messaoudi S; Fattal E; Vergnaud-Gauduchon J
Cancer Drug Resist; 2019; 2(3):381-398. PubMed ID: 35582577
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biological Activity of 3-(Heteroaryl)quinolin-2(1
Larghi EL; Bruneau A; Sauvage F; Alami M; Vergnaud-Gauduchon J; Messaoudi S
Molecules; 2022 Jan; 27(2):. PubMed ID: 35056725
[TBL] [Abstract][Full Text] [Related]
9. Novobiocin-ferrocene conjugates possessing anticancer and antiplasmodial activity independent of HSP90 inhibition.
Mbaba M; de la Mare JA; Sterrenberg JN; Kajewole D; Maharaj S; Edkins AL; Isaacs M; Hoppe HC; Khanye SD
J Biol Inorg Chem; 2019 Mar; 24(2):139-149. PubMed ID: 30542925
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerases as anticancer targets.
Delgado JL; Hsieh CM; Chan NL; Hiasa H
Biochem J; 2018 Jan; 475(2):373-398. PubMed ID: 29363591
[TBL] [Abstract][Full Text] [Related]
11. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
12. Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics methods.
Liu J; Wang F; Ma Z; Wang X; Wang Y
Int J Mol Sci; 2011 Jan; 12(2):946-70. PubMed ID: 21541036
[TBL] [Abstract][Full Text] [Related]
13. Targeting the dynamic HSP90 complex in cancer.
Trepel J; Mollapour M; Giaccone G; Neckers L
Nat Rev Cancer; 2010 Aug; 10(8):537-49. PubMed ID: 20651736
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and biophysical characterization of the Mg2+-induced 90-kDa heat shock protein oligomers.
Moullintraffort L; Bruneaux M; Nazabal A; Allegro D; Giudice E; Zal F; Peyrot V; Barbier P; Thomas D; Garnier C
J Biol Chem; 2010 May; 285(20):15100-15110. PubMed ID: 20228408
[TBL] [Abstract][Full Text] [Related]
15. The 90-kDa heat shock protein Hsp90 protects tubulin against thermal denaturation.
Weis F; Moullintraffort L; Heichette C; Chrétien D; Garnier C
J Biol Chem; 2010 Mar; 285(13):9525-9534. PubMed ID: 20110359
[TBL] [Abstract][Full Text] [Related]
16. Virtual prototyping study shows increased ATPase activity of Hsp90 to be the key determinant of cancer phenotype.
Vali S; Pallavi R; Kapoor S; Tatu U
Syst Synth Biol; 2010 Mar; 4(1):25-33. PubMed ID: 19856130
[TBL] [Abstract][Full Text] [Related]
17. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells.
Shelton SN; Shawgo ME; Matthews SB; Lu Y; Donnelly AC; Szabla K; Tanol M; Vielhauer GA; Rajewski RA; Matts RL; Blagg BS; Robertson JD
Mol Pharmacol; 2009 Dec; 76(6):1314-22. PubMed ID: 19741006
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.
Radanyi C; Le Bras G; Marsaud V; Peyrat JF; Messaoudi S; Catelli MG; Brion JD; Alami M; Renoir JM
Cancer Lett; 2009 Feb; 274(1):88-94. PubMed ID: 18842335
[TBL] [Abstract][Full Text] [Related]
19. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90.
Le Bras G; Radanyi C; Peyrat JF; Brion JD; Alami M; Marsaud V; Stella B; Renoir JM
J Med Chem; 2007 Nov; 50(24):6189-200. PubMed ID: 17979263
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
